Online inquiry

IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1627MR)

This product GTTS-WQ1627MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets F10&F9 gene. The antibody can be applied in Hemophilia A research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000504.4; NM_000133.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2159; 2158
UniProt ID P00742; P00740
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ1627MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ2176MR IVTScrip™ mRNA-Anti-IL15RA, ALT-803(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ALT-803
GTTS-WQ15705MR IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA VEGF Trap
GTTS-WQ7691MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GEXMab73
GTTS-WQ5609MR IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CDP791
GTTS-WQ231MR IVTScrip™ mRNA-Anti-B4GALNT1, 14.18 mAb(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA 14.18 mAb
GTTS-WQ15480MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA UCB-0107
GTTS-WQ2335MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ALXN6000
GTTS-WQ12714MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA OMP-305B83
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW